Skip to main content

Mind Medicine Inc(MMED-NE)
Cboe CA

Today's Change
Real-Time Last Update
Day Low4.2300
Day High4.3700
Open:4.2300
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Select a category then submit the form to load news
Business Wire
MindMed Reports First Quarter 2023 Financial Results and Business Highlights
Business Wire
MindMed Sends Letter to Shareholders Highlighting Company’s Positive Momentum and Value-Enhancing Strategy
Business Wire
MindMed to Host Conference Call and Webcast to Discuss First Quarter 2023 Financial Results and Provide Business Update
Business Wire
MindMed to Participate in May Investor Conferences
Business Wire
MindMed Files Preliminary Proxy Statement for 2023 Annual Meeting
Business Wire
MindMed Collaborators Announce Positive Topline Data from Phase 2 Trial of Lysergide (LSD) in Major Depressive Disorder (MDD)
Business Wire
MindMed Appoints Mark R. Sullivan as Chief Legal Officer and Corporate Secretary
Business Wire
MindMed Reports Full Year 2022 Financial Results and Business Highlights
Business Wire
MindMed to Participate in March Investor Conferences
PressReach
Psychedelic Drugs Prove Their Worth In Clinical Trials
PressReach
Colorado to Vote on Legalizing Psychoactives in November
Investor Brand Network
Psychedelic Therapies Offer Hope for Mental Health
Investor Brand Network
Mind Medicine (NASDAQ: MNMD) (NEO: MMED) to Study Effect of Time on LSD Microdosing
Business Wire
NEO Exchange Announces Eligibility In MSCI Indexes
Business Wire
NEO Exchange Announces Inclusion in FTSE Russell Indexes
Globe NewsWire
MindMed Announces Increase in Bought Deal Offering to Approximately $11.5 Million
Globe NewsWire
MindMed Announces $10 Million Bought Deal Equity Financing to Fund University Hospital Basel Collaboration
Business Wire
MindMed Lists on NEO to Become World’s First Psychedelic Pharmaceutical Company to Go Public

Profile

Mind Medicine Inc is a psychedelic medicine biotech company that discovers, develops, and deploys psychedelic inspired medicines and therapies to address addiction and mental illness. The company is assembling a compelling drug development pipeline of treatments based on psychedelic substances including Psilocybin, LSD, MDMA, DMT, and an Ibogaine derivative, 18-MC. The firm is having an approach towards developing the next generation of psychedelic inspired medicines and therapies.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2023.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2023 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.